SC
HRTX icon

Savitr Capital’s Heron Therapeutics HRTX Stock Holding History

Savitr Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$22.6M Sell
1,833,614
-23,147
-1% -$277K 39.64% 1
2014
Q1 		$25.8M Buy
+1,856,761
New +$24.8M 49.69% 1

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Savitr Capital's HRTX Position: Q2 2014 in Review

Savitr Capital reduced its Heron Therapeutics (HRTX) stake by 1.2% in Q2 2014, selling an estimated $277K and leaving 1,833,614 shares worth $22.6M. The position accounts for 39.64% of the portfolio, ranked #1.

Savitr Capital first reported a position in HRTX in Q1 2014 and has held it in 2 quarters since. The position peaked at $25.8M in Q1 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q2 2014.

  • Savitr Capital held 1,833,614 shares of Heron Therapeutics worth $22.6M as of Q2 2014.
  • Savitr Capital sold 23,147 Heron Therapeutics shares in Q2 2014, an estimated $277K.
  • Heron Therapeutics made up 39.64% of Savitr Capital's portfolio in Q2 2014, its #1 holding.
  • Savitr Capital first reported a position in Heron Therapeutics in Q1 2014 and has held it in 2 quarters since.
  • Savitr Capital's Heron Therapeutics position peaked at $25.8M in Q1 2014.
  • 69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2014.

Based on Savitr Capital's 13F filing for Q2 2014, filed 12 Aug 2014.